OA"

ANNEX
I{"epublic r:l' thc Philippincs
Dcparlnrent of Ilcalth
FOOD ANT} URUG AI)M IN IS'I'I{A'I'I()N

26 Ap ril ?$?2
t

{IAFISAR It, DLrL;tY

Coffirmissicr.ter
Rurs;ru ot' [nlet't1;ll lteveltlte
Queznn Citi,

SUHJ I'C]'I' E nd p rs g gr,e* [ _9.]1.,H. t u f .Y4J- Ii x * nr qL

prLp.&gl. Iris
" *'I e d ic i* q"t

lLr,fle*-Egp.uhlic -]ct,fBA]J_l5Jt., lqnon'n, ;ls eprpgr*jq

Beqoyef 'l:. 4 n rt ll"4 x, I rl f:e.n (ili$,UL3 p te f p ri{.g$ (..C R E 4',f '
S,}3 ct

Dear Commissioner llulay: "

,.
With ret-erence to the Iiirplemerlting $uidelines on tire Valuc-Adtiod Tax (VA'l') ijxeniption on
Sevcral Health Products provided under Joint Administrative Order (JAO) No. 2-2018 dated 2l
Decembcr 20I 8 aud JAO No. 2021 -0001 dated 23 June 2021, may we prnvide you with the updalcs
to the "l,ist oI'VAT-Exernpt Drugs fbr Hypeltension. L'anccr, Mcntal lllnusscs. Tuberculosis,
I(idncy Diseases. Diabetes, and High Chcrlcstcrol". Fuflhsr. DOH Departnreni M$urrlrandum No.
2021-0280 itas been issued, wherein all documents witir reference to the VAT-Exempt list of all
COVID- 19 rclated medicines antl meilical devices shall be lbrwarded to the F DA. Listed hereunder
are the updatcs. '

I. lior lnclusion

A. Sleclicines frlr' Hyper"tension

f,r:neric Name I)osagc litrcrrgth _---Ivl:sslerry

Ij'urossnr ide l0 nrglutl- Siolution lbr Injectiorr
(lh,til v)
Irhesartan '7
5" ntg 'l'ahlet
Labcta I ol I'I ydroclrloride 5 rrrg/nr I . Solution lirr )njecticn (l V )
( I00 ru9,20 nrl.)
I-eviitl, iirJipile (as besilate) ) nlg Tabl,ct
[-evarrr Jtriipiuc (as bcsiiate] 2.5 mg Tatrlct
--""" "-tl;r,'rrlrl*t
i

l'i;bi;irl,, i iis iivrrniriiriiiii-l t

t ;\rn , ., , lrinc (as bcsi latc)

I ; I

'l'elrni " ilrl -f i\rnlor{ipinc 'l'ablc.t

:.,, 8(i rrrg ;i1 u

busilatc)
'fcln:i , :, rirlt { r\rnloclipine ti0 nr gl 5
'l'ablet
| , . beslrlntc.)

B, iv''lcdicirr" ., for Diabetcs

i
I
x,ir *flllIu,- _ ._l Dasage Strcrr Htfl i
i

Dosilgr Fcrnr
I
I
I

,j
l,-..-
| (ilrr: ;rl;- IMctlorlnirr I

I
i
i
'['n h lcr
t
i
I

I lvdr. 'r'icic (ln liusl.arnr:ei- I

I
;
I
I
I

iciisc lrr:11 ) t
I
I
t

(livic f)rivo. Filiuvcst Corlloratc City., Alahanl{ l78l h4untinlupa, l}lrilil:pincs lntgfiqaemr]]l
Sv*t*rri
'lirtnk Lirrc +0.i 3 85 7 900 1 Fax +6-l I 807 A75l tSStl{Sti$flx$i",

Websitc : rvwr,l'. I da, gn1r. plr Hnrai I : infcf*,'lcla.gov.pll fr#|l,lhr {1iitn

$ qffisll4*t
 I l.i'r*ng [oilyd"tt., 5 nr1t I;i hl -(''oittsd J atilct
I h,-,,..,gt,nor.io iii; l;y.t,t-) F i lnr -Co*tcd'l-itblct

I Sitagliptirr (as phosphalc ?,5 rtt g i |jiltrt*('t-ra{ed'['itLrlet

i _ _*__$gllqlrytllirte )

C. illcrlicincs for Flii;h Chulestcrol

i Cencric N&nre llosngc $trcltgth Ilosnge fiornr

i F*nolilrrat$-t- Ro$uvastatin 160 rrig/10 nrg Fi1ur-Coaled l'atrlct
{as calciurn)
'l'ablct
i Fcnolilrr-ate * ltosuvastatin 16A u:gi20 mg F,l,"if;,t-d
(as calciuur)
ltosuvustatitr (as zirrc) ,,, I0 rngi l0 r:rg

nr"r*ort;ii'G';lfui; 20 mgll0 rug L *1:sulc

Ezetiuribe

[]. iVlcclicines fuir: Kidney Disesses

t_*_ Generic Nnmc iiui,'[* sffi;stl, Dosage li'orttt

ili etoanalogucs 'i' llssential I?or^mulation: I'mclr F ihn-Cloalerl
;\mincr Acids f ilm-coatcdtablet 'l-ablet
s0ntai ns Calc.ir.rnr -3 -
rlelhyl-2-oxo*
Vulcrtttc, ...,.,,,,, ()nl

ulg
(a -l{oturrrla iogue tcr
Lsoluucittc, calciut:r
salt) Cak:ium-4-
rncthyl -?-0xu - v eilerate
.....101 rng
((, -Kctc':iltralcgur: ttr
Lcucinc, calciurn salt )

C'aiciuru-2-rtxu*.3 -
Phcnylpropiattate
..68 nrg
(ii-It$t r-)aualoguc t o
Ilhcnylalaninc, iaiciurn
saltl Calciunr-3-
nr etir5'l -2-oxo- butyrate
,""a,'86 ttrg
(a- l(ctnanalogue to
Valin*, calciunr salt)

F;. h'I cd ic rrr r'', for' ['l cntal illncsscs

l)osngc Sfrcngtlr
- it;;*s- I,1r,,;
250 rrrgfinl s,Jtti*,;m
(ll't l\/}
i 'iliiii*l'l'ahljit
t*-*
Cili;tiline 1Po 1tg _ *j__ *_lf i; i
t
I

i
5U nig
t---
I
t
t
I
I t rng/ l0 cui?
I

I
t.__
{9.5 msl24 hours}

t[Uplr-i"i ;il;iilnil;r ftri;i ,,,rFl Pagc I of B

l'-
t' i -i' i I
i,. l i

i t 7
l,' .' . i
I

4"$r
 ItivastiHnrinc (")
rng15 cr:r '[ransr.lcnnal Patu]r

!1,!111{/-lu horlrs)
Vrifi itlxet ine 5 nrg F ilur-( lnatcd 'l'nblct
(as hJclrr"rbronildg)
*Tir*rabJe'I-nG
Vortioxetine I [i rng
(,1.1' ltydrurl:yonlid*)
Vorlinxetirre --
l) r:ts Ijil nr -(loal etl' I'ablcl
{as hyclro[:rr:rnidc)
Vor"tioxetine 2A r11g F ihn-Clo*tecl Tatrlst
(as hyclrolrrouricle)
/,{trlrstttnirh3 100 nig Capsulc
Zorrisaluicle 50 lng Capsu lc
Zonisanricle 25 nl p; ! [-o{s

tr,'* h'tecticines tor Tuberculosis

Generic iq*ladre" '' Dosage Strength Dosilge For"ln

I*gS lli c[+ Pyrlcltl x i 1 c 200 ,,sltt ;rrsls ;;i.-- Syn"rp (pr ange Fli1,'trf)
R i fanrlr i ci n* Iso n iazid+ 150 rng / 75 mg F ilrrr-(loat ecl'I';rhl el
Py razin am icle{- Et}rarnb u tol i400 nrp.i275mg
^ iliiiiiiipi'iii + i.i,,iii,,ri.t
HCI
loo ,i,glt sb ,ire Tutri*l
Itif ampicin I Isoni azid + I 50 nrg/ 75 rrrgi Ij i hn -(loated'l'nb et I

h tllap lryto I I Iychnch I oride 275 rng

G, Pledicines ['or Cnncer

---D;*og"6ii*fih "*Dm-g-
Cencric Nanre rorn;*-
Abernaciclib 50 nrg Fihn-Coatecl I ablet
Abenraciclih 100 mg Fihn-C'oatcd "fahlct
Aber::aciclib I50 mg Filrn-Coated Ta[rIet
rt bemaciclib 7$$ mg F ihn-(. oated' ['ahrlet
AIpe Iisih 20A r11g Fi Iur-(loilted'l'abIet
(200 il]g Daily Dose)
Alpclisih 25$ nlg + 50 rr:g Filni-( lnated Tablct
(.250 nrg claily
dusc)
Alpelisil: I 50 ms -l- 150 Fihn-Coated Tablet
nrg (100 ,)lg
riaiiy closc)
Do*ctaxcl (as trihydrate) 40 rnEfutl, Cnncentrate Solufitrn ltrr I V
Infirsior:
I )ox*l'u[: i ci n H yclrochlor:i dtl 3 mgim[. (5{) Solution fbr Liposurnal
rng/25 rl L) Ini cction (l\r)
lJ t.r rttt'u lr i c i n I-l vdnr chlnrr rlc ) mstnrl (20 Solutinn firr I.iposnmal
rrtgi l(l mL) Injcction (lV)
lJoxrni ["r i r- i :r ]-l t dror:hloricle i0 mg Lyoph ili zctl Po r,r,d er lir r
ln je ction t [V trnfirsicrn)
li nzalutanricle 40 rng Capsule

Pagr' 3 of'll
,, i.,r ;

r5 ,\f
i

{n
I
T

I
i
!-_
I
lt r
*-t
 h,pirubicin 2 rrrg/rnl { I0 Cbnccntratr Siolutiorr tbr
rngiS ntl-,) Irr jectimr ( LV ilntravcsical)

h,pi lul:icin I lyclrocl:loricIe 2mglmL Conccntratc St:rlutiott for

lnj cctiorr ( IVi hrtravcsical)
I;l uorcl urasil 25 rnglml Soh-rtinn For- Injection (lV)
t {25$ r"ng 10 mL)
Gctitinib 254 mg 'l'ablet
Ltlnaliclornide 5 rng Ciapsule
Lcnaiiclornicle l0 mg Capsule
Lenalidomide tr5 mg Cnpsule
I..cnaliclturide 25 mg Capsr.rlc
Onclansetrurn (as 2 mglntl , {1 wtglZ rrrl,) 5oluLion For Inieutiun
It1,'ch'cch I o ride d i hyctratc ) (t,M,tI"v.,
Clxaliplatin 2m{mL Concenlratc Serlution fbr
lnj ec.tion
(lV trnfusion)
Paclitaxei I00 mg Lyoph tlizetl Porl, der Fo I
(I.V. lnlusion)
Palonosetron (as 50 rnc glnrL Solution lbr I.V. Injcction
hyclrochloricl*) t7S nrcg/I.5 mL)
[]alonosslron ('as 50 rncgftnl Solutir.lu tor lutravenous
1r yclro*hloriclc) (2510 mcgl5 rnl) lniectiorr
Paz*panil: 20A r11g l.,'i I rn-Coatecl'l'ablet
( as hydrochloride)
Pazopanill 4t)0 ilrg Fihn-(-oated Tablet
(as hvclrordrluride)
Per:rctr$xer1 (as disodiurn) 1g Lyophilized Pcwcler For
Solution l?or IV Irrftlsion
Tilcilizr-rnrab 80 rngl4 mL" tZA Concentratc For Solution
mglml,) For Infr"rsion (tV)
l.ucilizumab 162 mgl 0.q rnL ,Solution Iror Injectinn ($Ci
Tcpotecarl I mglrrrl- Cunccntralc Solutir.rn fbr lV
(as hyclrochloricle) h-r Ir"rsiort
V innr*iirinc (as tartrate) 3 0 r:rg Softgr:l capsule

rI. ['Icdicilrcs tor COVID-I ]l treatnrsnt

{ l encric i\ ftru Dosagc $i(rength

-_*-__g"rssl:m-^. - j
L.

.tr:rr,xicillin 250 rrrg Capsu lc i

{as 'l'r-ih.r-drate}
r\nrpriciitin las sodiunl) -i I g/Silfi nrg P"",rl* l*G;;;;;
S uIbar-:tanr (as sr:cl iuryJ {l.v,il.h,I.)
,{n:pici I Iin ti* ic,cf iiinil i '
500 mg / 350 rng Porvclcr {br Injcction
Sil jhar-:l;lrtr (as socliHrri)
*-
Anrpicillur (a.q socliunr) t P*;cfi;:rui lr;--ir*--
I r,lhacten: (ns socliupr )
(lMilv)
,\r'npr,:il i n { ar r"iiiri;;ri l-
1 75(,l lrrr,. Stcrils Porvdg fbr'
Sirll.nctai r i { ns sodiurn} Inj e ct ir:n
;\tnpiuiliin (as sodiunr) +" 1.5 g (1g + 500 g,) I'nrvclcr lor Injcctian
$u llractar:l (as soriiurn) V}
-[fl*Hr';tiffiryt5
llr,
!ii ',, I I'agc 4 *l'8

$t 16 {,o
 i A,lpicillin (as sodium) - I
:

l"-
I.{ r, I)urvder lbr Inieutiuu
ii- SulLractarn (as sc,cliunr) I
(rMilv)
.i. ....-.-
t, "_...

i ,\mpicillin (as sodiurn ) + ; 1 gi500 I',",*&

i

i (lv/lM)
_ Sylhtctam ias.,sdjuill
i Atracurium (as besilate) lo *gfurl Srrlr,tt",, 1b.1,
I

rr,) {I.v.)
,fti:at*iu,r*"ifut* -l3lr*il'l
l0 nrg/ml, s;i'iii;'i iil i,uilii*iii iiii
l.V. Inlirsir:rr
t,-
I

i
ll utJeson icle ----J:!-ugfglr)
'25$ ntcg/tttl , Suspension lbr
I
(
I (500 rncglZ rrrl ,) Nelrulization
i
I

i
Budesonicle :oij i,*,a- Pres su ri't*d M st cr"ctl
I

I
Dosc Inhalcr'

I n;,l"**irl- 25{) mcglnrl Suspen.rion for

I
(500 rncgirnl,) l',1elru lizati*n
i
,

I
lludcsorr iclc 200 rncg IJry llou'cler in Ca;rsul*
i
l. tor 0rrrI Inhalntiort
Rr.lde.sauicle 500 rncgirul-, I! ebu li'ti ng Su spertsi on
( I 000 m*glT rnl) (Sreril*)
lJucleson de 200 nicg per Achration Meterecl DoseInhaler
Budeson de 250 rtrcg/nr L " " Rflpirittory' Sgspcnsion
lludesonidc .200 mcg N4etcrcri I )osc Inhalal.iern
lJudesorride (:4 mcg pcr actuation Aqueous Nasai Spra1,
Buclesor:ide 200 nrcgrcloxe I:)owcler lor 1nhalatir-rrr
B sorricle / Fomrate rr:1
r,rcle 80 rncg 11.5 mcg P0 u,cler lirr Inha latiorr
Fuurarate Dilryclrate
I
I
I}ucl*sonide i Fonnoteroi , 320 mcg I 9 rr:cg per dosc tr)owdcr ftl- Inhalation
It,.*- Fumaratr: Diirydrate
iI
fJurlcrsorritie'"1- Z$A mcgi6 nlcg I)r'1' Pr:wclet- firr

j
I ltomroterol Furrrar ate Inlurlatit"rn
I Dilrydrati;
I
I
ij
Ce lazoiin (as socliurn) 500 mg Porvdcr Ior Injecticn
t
I
I
t
(IVIIMi
i ['clcpiit:,: {i,. i,i;.t"r.irtrr, t.Ul lg Pr.lrvrJcr fbr Inj*ct iorr
i

{1,tuI,i1,V,1
I

C *icirinl(' {'ar; irl,,drochloride } )rt lrorvclcr f'or Inicctirn

(lvilM)
! gi'*pilll! !n' I:ychnch.lorife) 5(i[] nrq Powcler lirr In jection {IVilful)I
" - - -i
('ulirt;,r'; ii r,i,: {.;rr; stlcliurrr) Is i{;"'.ri':iiti:i,t1i,*iffi
(lMiIV.) i

( leihtaxinre (as soclium ) 500 n:g Porvdcr lirr Inicctinn (trfulilV)

('trirrt;rx iri ;c { ;is sorlir,rrn } 25fi nrg Porvrlel" I'bt' Injeclion (tVi lM)
('* I riilx r ,iii I its sod iunr ) 1o
,t: l,.,i"ir*i ii,i iru iliii,;i
(lV lufusirur)
r"* ii tiri.ii i: i,-. i,,
"
pr',rru lu Ilawdcr {irr Injcction {lVilM)
{',;:il ;t/ t;.ii I; t,, (, l:, l",i,itlirtiiilL:,1 500 rng Porvclcr {irr Injcr:tiun {lfulil\i)
L'uli;tzitliur,-: { lrs pcn tahyclratc) lrr Ilorvdcr fbr I.V. I n t-us ion
l*titi,ir,,,i., tj,.; Sod i unr ) 1g Ilorvrlcr lirr Injcctiorr (lM/lV)
('c l1ri iixilrlil ( as Sorl iuun) ao Porvder lirr Injcctiun (lMllv)
ile firlil.\{uie (as riodiunr } lgi 50() nrg Porvdcr li:rr I njec:tion (I i\,lilV )
- sl l1:,1lti
iilll !iu_ s:-t_tligd. .,"__
{'cfir"i;tx$llc las sclrliunr} 500 rrrg Ilog,der lbr In jectinrr (l lt-4/lI')

{if: lfjTrf}}},1 I i?f\li:i,JlJf

Irlgc 5 ol" f{

{
q^. l$ ,{tlt
a

..,, ..]
I
I
{-le fh roxinrc (a s axct il ) 500 mg
I

Clc f"irrnxinr e {as sodiunr ) 1.5 g Pou,cler ltrr Iuieclion

!:yl*qIIu:.3l:sgsl 750 n:g Pou,der {i:r h1jcction (IfuI,'lV)

{-lctiu oxiine (as axctil) ?5$ rr:slS nrL I'i, rvri*i ii,il s uirr*,r*iriii--
Ceiuroxime (as axetil) 125 rngi5 nrl Irnu,dcr lirr Suspcnsi orr
Llefirroxime (as axetil) 125 urg/S url Powder firr Oral Susl:er:siorr
Cethroxirue (as axetil) Grarrules {br Or-al Suspcnsiorr
lig$i*illi-*-j*"ry,tgiiU l5(i ursr5 ruL Irowrter ft,r Cr"rl St
Cef uroxime (as axetil) 25i) mul5,rrL Cranules fi;r Oral Suspension
Celum;xiine A.xetil
_-___-cipruitoi*i,t- i00 rn u Fil rrr -(loafcd' I'ahlet
I

rn ui rn [- Solution lbr Injectinn

(as irydr ochloriclc) rr7A(i rng/100 rrrl) (lV In{irsion}
Cipro lJoxacin 500 rng l';iln: -(loalect
'I'at-rle
r i
i

{as lrydrochioriclc)
i
I

Ciprofloxacirr 750 mg I'illir-fl]oateri"[';ahlct i

(as hydroshloride)
L:iprof'loxacin 3 rugirnL Solutinn frrr IV lrrfusion
(as hyrlrochloridc)
Cllirrrianrycin 3,00 rng Clapsu le t

as hydr n*hloride
Clinclarnyciu I 5n rnginr[.-
--
.q;;ilti;;;i ft;;ri,ii;ii,;
- i

as phosrlutl.e (l.ivI.il,v.1
Cllinclanrycin 150 nrg Capsr;lc i
i

as hydr'cchloriclc) i
i

Dalteparin Sodiurn 25tit) ru/O.J rnl, Solutiorr l;or lr:jection (SC)

Ilcxanrcthasttnc -l nig/rnL $olutir:n Fr:r hr icct ir:n
( H rng/? tn[ , (rMirv)
I)cxarncthasonc -l rrrg/rrrl- Salution l'or lnjcction (tVllM
Phosphate {as sodiurrr
Hnoxerltarin sodirurr
$ y I $ i p [f u-t, { ttj g-g ttgljElz-''n'
6il rnsl0.6 nrl-
linoxaparin sodium 40 nrul0,4 rnl Solulion For Injection tSO ---*{
Ilnoxatrlnrin sodiunl +1100 II"i $oluti*n li:r lrrjection (IV/'SC)
4{i rng)/0,4 rriL
Enoxaparin Socliurn tu"000 IU ,Solution For Injcction
({r(.i n:g ifi.$ m[,) (ruisc)
::tro.'"it1::tri
I n Sitdium Solution {trr [u.jr;ction (SCl)
!:n*xril)il ri n Sod iurn t ;\v10.2 nt [ ,
- F,?-lr!iu: lpy birsioJ! 1,ry !:IC,
I: entnn1.l (ris ;iidG:i* 100 Iri, ;- r*.ruiu,r*,:ii i" Sublingual 'l'al:lct i
i
15r. i rlrcg l;cntanyl i

I-;cirt lr ni,l {as citr atc} . ir(lUivalcnt

a
t* 3I 4 Suhlingual 'l'*t:let
t]l{:-: i ;ntanyl citr-atc}
Fenlrtl\r' [ ( as citral.ei Scllulion fiir Itricct iort IVlSCI
F cntarl;,1 (ns citlatc) Solution lirr Ir-riectitrr TMITV
I,'ent ;inyl as citrate)
1
jt; rn cglml Sulutiun lirr Irrjcctiou (IM/IV)
- U ti{i mcglZ n:L)
r [,],i'i,iyr ioi-iiiini*i I(iti tncgl? tn[, Solution {irr hrjection (ltuIi IV)
151 nrcg/nrl)
l;on,"i lr 1:;rriirux Sodiurn {
.Sr:iutiorr tilr Injcctir:n (S( l)
{i. J nrdnil,}
7.5 ri; _ ;.i.6 nrl { l2.j .{i,i',iirn ini irli**li,'in lidl
I;nndaparinux Sodiurn
ryL
irsip:r EI_
ItIi, I.j IF lt'Jfq!:? nii.
r I ft f \iIr'tLJf
.t

I'agc 6 t.tl- 8

"t

/)-
T. ls vn
 {12:5 rngin:L;l
IIe:;:;rrirr sodiurrr l{}00 ItJinrl. Solul iur t {i.x' I rrjectinrr ( IVlSq}
Levotloxacirr 500 rng/l00 mL Siolution fbr" tV Infhsicur
l,cl,of loxitcin (ns lrern ihydrate) 5 rn yf n{, Solutit>tr lirr tV It:{'usinrt
G",ii**il i-ffi,rlt yrtrrt-r 500 rng I' i I nr -Coated'["a[rlet
Lrlvo{ioxacir r (as lleurihyclratr:) 250 nrg, F i lrrr-(.loater:l l";rhl et
"['a
[-,r\'o f]oxacin ( as hemihydrate) 750 rns I;i lru -Cloatcd blet
Lc,T,o flclxacin (;ls hern ilrych'ate) 5 rrrg/5 nrl Solut ir.trt lor iutravcllous
(5(l() nrg/100 nrl-) inlLsion
l .evolloxacin (as herniirydrate) 5 rnginrL lbr intra t'elltrlls
Sol ul.icrn
(500 mglll00 url-) inlirsion
urnpcncill
h{ ts Porvclsr Fur In_isclion (lYj
Il{cropsnclrl ( as trilry<lratc) ls Purvcler For Injcction (lV)
h,'l crope r1cr11 500 rng Sterile Porvder lor Irrier:tion
MetroniCazotrc 500 nrg ,i l$() rnl. Solut ion For lrt.jr:ctiort
(0.5('n w/v)
rr:niilazole (as U*nhaale)',
N'l cl 125 mg I 5 rrrl {}r'3t
It orep inepl'lrine (as bitarlrate) I rns,i nr I.. Solution
(4 rurgi4 nrl-)
N r:repincplrine (ns bi tartratc) I rrrgi rn L Ct:rtceulrrrte ltrrIV lnIusion
1! orcpineplrI ine (ars tritar-tratc) L rtg,]l[. Solutior: Ii:r' Injcction
hior"cl: incl:lrri nc ('as bi tartr"ate) '1 fi1g1fu [, Cloncentrate fiir Solution Ior
(4 rnsr-i rn L; IV Inllsion
l)iperacillin (as .socliurn) * 4 gl50Ll nrg Irowder krr [n^icction (lVi
azuhactam (ars sodi u rn )
1'
Piyreracillin (as socliurn) -1" a 91500 rng Por.vder for IV Inlusion
'I'azobautam fas r*ocl i un:J
Iliperacillin (as sodium) * 2 gl25l) rng Por,r,dcr fbr lV Infusion
Tazohactam (as sodiurn)
I)iperacillin (as socliunr) -t- '[
? g l25t) urg Powder: l'or' [niection (lV)
r pze haq s;,1fffl?rt iu rsl _
i 00 rirg Lyophilizecl llor,vde r fcrr
Inicctiou ftrt' I.V. lrrfusion
I(ocurunium Bri:rniclc i(l ntili rui l
Solutir"rn for Iniectiorr (lV)
i,;,i:,.,iiiry"iii ls Powcler for iniection (1.V.)
\,'itrlcoln1.c irt
:-* -so!l ry;3. Parvclcr- f?x In iectir:rr (1. V.l
{l,ii r r r, r, i ;,'i i,, f ii r ty iii:.i rrii iii i ;il] 50fi nrt Ilowcler lior In.icction t'lV)
\'r ilrlcolrl 1,c in (a s |yclrocfu lclride) 1 Pr:u,rlcr l;r:lr Irr,iectir:q (lV) j

\,'anuortrvuin i as hydrochloriclc ) 50{ i l,ycrplt ilizcd l)owclcr" tbr. IV i

*
itu,iio,i, .;* il-i," ir),d"r.lrt0", e) I I (Xii , ,ii:l

-*?;;;;ilfi; -^:
hlicgljttt, I ttr; i

; ffi 1
L,*.1," r t,t.i iiir- r ){)i rill.,l
.

Powc"lcr lor llrjc:ction

--(lv lrfuinU
I

..* .*. i
\1, -,", *;;;;; ;l[,d r,.,ctri"iii-i
r i'
,

t. f'olrydur f or Injcctirr,:i j

( lV lnfirsinn ) i

[]nge 7 ol'f;
Shuulel yoLt have any eluestions/clarificatiorrs. kinclly adclrcss thern to thc fDA llolicy *ncl
I'lanuing Serrri ce at pps@fcla. gov.ph.

T'irank you i.ely much.

Vcr:y truly r.rollt'$r

f)R. OSC, R 7,, JR.

O l'{icer-in- Directn Ceneral

i'lge l{ trl'8